Can a cholesterol drug help immunotherapy work again in lung cancer?
NCT ID NCT05553834
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy drug (cemiplimab) can shrink tumors in people with advanced lung cancer whose disease got worse after standard immunotherapy. About 60 participants will receive both drugs every few weeks. The main goal is to see how many patients respond to the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alirocumab and cemiplimab combination
What this could lead to
If successful, this could offer a new treatment option for people with lung cancer that stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial (60 people) with no control group. The combination may not work better than existing treatments and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27705, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States